Evidence map›Paper›PMID 31755044›Full record

ArticleJournal of the American Society for Mass Spectrometry2019

Deep Intact Proteoform Characterization in Human Cell Lysate Using High-pH and Low-pH Reversed-Phase Liquid Chromatography.

Dahang Yu, Zhe Wang, Kellye A Cupp-Sutton, Xiaowen Liu, Si Wu

Abstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Multidimensional Separations in Top-Down Proteomics.Analytical science advances · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. RPLC-RPLC-MS/MS for Proteoform Identification.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  16. Post-translational Modifications in Parkinson's Disease.Advances in experimental medicine and biology · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dahang YuDepartment of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Room 2210, Norman, OK, 73019-5251, USA.
Zhe WangDepartment of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Room 2210, Norman, OK, 73019-5251, USA.
Kellye A Cupp-SuttonDepartment of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Room 2210, Norman, OK, 73019-5251, USA.
Xiaowen LiuSchool of Informatics and Computing, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202, USA.
Si WuDepartment of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Room 2210, Norman, OK, 73019-5251, USA. si.wu@ou.edu.ORCID http://orcid.org/0000-0002-6346-7359

Funding

Defining the role of altered cytokine signaling pathways on autoimmunityU01AI101990 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2016
$12.1M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Computational tools for top down mass spectrometry based proteoform identification and proteogenomicsR01GM118470 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Xiaowen Liu · 2016 to 2026
$2.7M
Quantitative Analysis of Serum Autoantibody Repertories in Systemic Lupus ErythematosusR01AI141625 · NIAID · UNIVERSITY OF OKLAHOMA · PI SINGH, SHANTERI, SMITH, KENNETH MICHAEL · 2019 to 2023
$2.1M
National Institute of Allergy and Infectious Diseases R01AI141625NIAID NIH HHS R01 AI141625NIAID NIH HHS U01 AI101990NIAID NIH HHS U19 AI082714NIGMS NIH HHS R01 GM118470NIGMS NIH HHS R01GM118470Oklahoma Center for the Advancement of Science and Technology HR16-125University of Oklahoma FIP
6 · The paper itself

Abstract

Post-translational modifications (PTMs) play critical roles in biological processes and have significant effects on the structures and dynamics of proteins. Top-down proteomics methods were developed for and applied to the study of intact proteins and their PTMs in human samples. However, the large dynamic range and complexity of human samples makes the study of human proteins challenging. To address these challenges, we developed a 2D pH RP/RPLC-MS/MS technique that fuses high-resolution separation and intact protein characterization to study the human proteins in HeLa cell lysate. Our results provide a deep coverage of soluble proteins in human cancer cells. Compared to 225 proteoforms from 124 proteins identified when 1D separation was used, 2778 proteoforms from 628 proteins were detected and characterized using our 2D separation method. Many proteoforms with critically functional PTMs including phosphorylation were characterized. Additionally, we present the first detection of intact human GcvH proteoforms with rare modifications such as octanoylation and lipoylation. Overall, the increase in the number of proteoforms identified using 2DLC separation is largely due to the reduction in sample complexity through improved separation resolution, which enables the detection of low-abundance PTM-modified proteoforms. We demonstrate here that 2D pH RP/RPLC is an effective technique to analyze complex protein samples using top-down proteomics.

Indexed as

Chromatography, Reverse-PhaseHeLa CellsHumansHydrogen-Ion ConcentrationPhosphorylationProtein Processing, Post-TranslationalProteomeProteomicsTandem Mass SpectrometryProteomeIntact proteoformsLiquid chromatographyMass spectrometryRPLCTop-down proteomics

Identifiers

PMID31755044
PMCPMC7539543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.